Talphera Reports Q2 2026 Earnings and Clinical Trial Progress
Talphera (TLPH) reported financial results for the second quarter of 2026, including a net loss of $4.3 million compared to $3.5 million in the same period last year. The company's cash reserves stood at $17.1 million as of June 30, down from $20.4 million by December 31, 2025. Non-GAAP operating expenses increased due to higher clinical trial activity. The NEPHRO CRRT registrational study reached 75% enrollment and is on track for completion by the end of 2026. The company expects top-line data in Q4 2026, with a PMA submission planned for early 2027. Updated market research now estimates 200,000 annual CRRT procedures in the U.S., up from 165,000 previously. Talphera highlighted recent inclusion of nafamostat in international clinical guidelines and is preparing a commercial launch strategy supported by conditional financing tranches totaling $16 million. CorMedix Inc. has also secured a right to negotiate for the drug's U.S. commercialization following data release.
Tickers: $CRMD
Topics: capital raising cash flow clinical trials market research